8-KShareholder MattersOther Events

Edwards Lifesciences Corp 8-K Report, Shareholder Vote Results (May 8, 2019)

Filed May 8, 2019For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences Corp. (EW) details the outcomes of their 2019 Annual Meeting of Stockholders and significant capital allocation actions. The meeting saw the election of all director nominees, approval of executive compensation on an advisory basis, and ratification of PricewaterhouseCoopers LLP as the independent auditor. However, a non-binding advisory proposal regarding an independent chair policy did not pass. More notably for investors, the company announced an Accelerated Share Repurchase (ASR) agreement on May 2, 2019, to buy back $150 million of its common stock, with an initial receipt of approximately 672,000 shares. Furthermore, on May 8, 2019, the Board authorized an additional $1 billion for share repurchases, bringing the total remaining authorization to $1.3 billion. These actions signal a strong commitment to returning capital to shareholders and reflect confidence in the company's financial health and future prospects.

Key Highlights

  • 1All director nominees were successfully elected to serve one-year terms at the 2019 Annual Meeting of Stockholders.
  • 2A non-binding advisory proposal on executive compensation was approved by stockholders.
  • 3The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2019 was ratified.
  • 4A non-binding advisory stockholder proposal for an independent chair policy was not approved.
  • 5Edwards Lifesciences entered into an Accelerated Share Repurchase (ASR) agreement to repurchase $150 million of its common stock.
  • 6The Board of Directors authorized an additional $1 billion for share repurchases.
  • 7The total remaining authorization for share repurchases now stands at $1.3 billion, indicating a significant capital return strategy.

Frequently Asked Questions

At the meeting held on May 8, 2019, all director nominees were elected, the company's executive compensation plan received advisory approval, and PricewaterhouseCoopers LLP was ratified as the independent auditor. However, a proposal for an independent chair policy did not receive stockholder approval.

An ASR is an agreement where a company repurchases a substantial amount of its own stock immediately, rather than over a prolonged period. The $150 million ASR announced signifies a swift execution of capital return to shareholders and demonstrates the company's confidence in its stock valuation.

Edwards Lifesciences has authorized an additional $1 billion for share repurchases, on top of the $150 million under the ASR agreement. This brings the total available authorization for stock buybacks to $1.3 billion, indicating a robust capital allocation strategy.

A substantial repurchase authorization of $1.3 billion suggests the company plans to actively reduce its outstanding share count. This can potentially increase earnings per share (EPS) and shareholder value, provided the company repurchases shares at attractive prices.